Investigational drug · Phase 3
HMPL-306
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Acute Myeloid Leukemia, Grade 2 Astrocytoma or Oligodendroglioma With an IDH1 or IDH2 Mutation.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
7
Any phase or sponsor naming "HMPL-306"
First trial start
2024
Apr 26, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "HMPL-306", any sponsor or status.
Conditions studied
As listed on its trial records.
- Acute Myeloid Leukemia
- Grade 2 Astrocytoma or Oligodendroglioma With an IDH1 or IDH2 Mutation
Approved drugs for the same conditions: Brain tumors (glioma) · Acute myeloid leukemia · Oncology · Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "HMPL-306" as an intervention, largest first.
- A Study to Evaluate HMPL-306 in Patients With IDH1or IDH2-mutated Acute Myeloid LeukemiaPivotal-lookingRecruiting
HutchmedIndustry
NCT06387069 · 316 participants (planned) · Start Apr 26, 2024 · Primary completion Dec 31, 2028
Drug: HMPL-306 Regimen; Salvage Chemotherapy Regimen · For: Acute Myeloid Leukemia
Sites: Hefei, China; Beijing, China; Chongqing, China · 53 sites in all
- HMPL-306 in Participants With Postoperative Residual or Recurrent Grade 2 Glioma Harboring IDH1 or IDH2 MutationsPivotal-lookingNot yet recruiting
HutchmedIndustry
NCT07912398 · 210 participants (planned) · Start Nov 2026 · Primary completion Mar 2032
Drug: HMPL-306 tablet; Placebo · For: Grade 2 Astrocytoma or Oligodendroglioma With an IDH1 or IDH2 Mutation
- A Study of HMPL-306 in Patients With IDH1 and/or IDH2 Mutation of Relapsed/Refractory Myeloid Leukemia/NeoplasmsStatus unknown
Hutchison Medipharma LimitedIndustry
NCT04272957 · 75 participants (planned) · Start May 14, 2020 · Primary completion Jun 30, 2021
Drug: HMPL-306 · For: Acute Myeloid Leukemia
Sites: Beijing, China
HutchmedIndustry
NCT07025018 · 52 participants (planned) · Start Jul 15, 2025 · Primary completion Dec 2026
Drug: HMPL-306 · For: Gliomas Harboring IDH1 and/or IDH2 Mutations
Sites: Shanghai, China
HutchmedIndustry
NCT04764474 · 46 participants · Start Apr 12, 2021 · Primary completion Jan 15, 2025
Drug: HMPL-306 · For: Isocitrate Dehydrogenase Gene Mutation
Sites: Orange, California; Atlanta, Georgia; Worcester, Massachusetts · 15 sites in all
HutchmedIndustry
NCT04762602 · 42 participants · Start Feb 28, 2021 · Primary completion Feb 27, 2025
Drug: HMPL-306 · For: Isocitrate Dehydrogenase Gene Mutation
Sites: Santa Monica, California; Atlanta, Georgia; Iowa City, Iowa · 11 sites in all
HutchmedIndustry
NCT06671873 · 6 participants · Start Nov 26, 2024 · Primary completion Feb 28, 2025
Drug: 100 µCi [14C] HMPL-306 · For: Mass Balance Study
Sites: Jinan, China
Newest research
PubMed records naming it or its code names, newest first.
- A Phase 1, Open-Label, Multicenter Study of HMPL-306 in Advanced Acute Myeloid Leukemia With Isocitrate Dehydrogenase Mutations.
Montesinos P, Sangerman MA, Pierola AA, et al. · Clin Lymphoma Myeloma Leuk 2026
- More than just another IDH inhibitor: Insights from the HMPL-306 phase 1 trial.
Getz TM, Bewersdorf JP · Med 2025
- HMPL-306 in relapsed or refractory IDH1- and/or IDH2-mutated acute myeloid leukemia: A phase 1 study.
Hu L, Wei X, Zhao W, et al. · Med 2025
- Discovery of HMPL-306 (Ranosidenib), a New Potent and Selective Dual Inhibitor of Mutant IDH1 and 2 in Clinical Development for Cancer Treatment.
Xiao K, Zhang Z, Wu Y, et al. · ACS Med Chem Lett 2025
Also in development for Acute Myeloid Leukemia
- AK117Phase 314 trials
Akeso · Advanced Malignant Tumors, ACUTE MYELOID LEUKEMIA; AML, Higher-risk Myelodysplastic Syndromes
- BL-M11D1Phase 32 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Acute Myeloid Leukemia, Myelodysplastic Syndromes
- GM-CSFPhase 32 trials
Y-mAbs Therapeutics · Neuroblastoma, Acute Myeloid Leukemia
- ASTX030cedazuridine + azacitidinePhase 31 trial
Taiho Oncology, Inc. · Myelodysplastic Syndromes, Acute Myeloid Leukemia, Myelodysplastic Syndrome/Neoplasm
- RVU120SEL120Phase 23 trials
Ryvu Therapeutics SA · Advanced Solid Tumors, Acute Myeloid Leukaemia (AML), High-risk Myelodysplastic Syndrome
- bexmarilimabFP-1305Phase 22 trials
Faron Pharmaceuticals Ltd · Higher Risk Myelodysplastic Syndromes, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia
- IMGN632Phase 22 trials
AbbVie · Blastic Plasmacytoid Dendritic Cell Neoplasm, Myeloproliferative Neoplasm, Acute Myeloid Leukemia
- CFI-400945Phase 21 trial
Treadwell Therapeutics, Inc · Acute Myeloid Leukemia, Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.